Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. NATCO Pharma Limited
EIR
•NATCO Pharma Limited•June 19, 2025

NATCO Pharma Limited – FDA EIR, Jun 19, 2025

Record Details

An FDA inspection of NATCO Pharma Limited, located in Rangareddy, Telangana, India, was conducted from June 9 to June 19, 2025. This unannounced, for-cause inspection focused on sterile and non-sterile drug manufacturing, following guidelines such as CP 7356.002 and 7356.002A for drug manufacturing and sterile drug process inspections. The inspection identified seven significant violations, documented in an FDA 483 form.

Key issues included critical deficiencies in the environmental monitoring system for aseptic processing areas, specifically concerning data integrity. Instances were noted where electronic data for non-viable particle counts were altered from failing to passing results in official hardcopy reports attached to batch records. Additionally, retesting without proper justification or documentation, and the omission of relevant environmental monitoring data from batch documentation, were observed. Other violations included inadequate maintenance of equipment and utensils, insufficient validation of aseptic processes, and a repeated failure to thoroughly investigate unexplained discrepancies and batch specification failures. Furthermore, the company lacked established and followed procedures to prevent microbiological contamination in sterile products, had unsuitable building construction for proper operations, and exhibited deficiencies in written procedures for its quality control unit.

NATCO Pharma Limited management acknowledged the observations and committed to implementing corrective actions, with a written response due within 15 business days.

Company
NATCO Pharma Limited
Inspection date
June 19, 2025
Product type
drugs
Office
Center for Drug Evaluation and Research
People
  • Sandeep Kumar (recipient)
  • Arsen Karapetyan
  • Wayne D. Mcgrath
  • Nannapaneni Rajeev (recipient)
  • Glenda J. Bryant (company_representative)
View Company Profile

ID · 15752826-391f-4aff-bfa9-bbb8405c68d4

Violation Codes9
21 CFR 211.113(b)21 CFR 211.42(a)21 CFR 211.42(c)(10)(iv)21.U.S.C. 355(a)21 CFR 21121 CFR 211.67(a)21 CFR 211.19221 CFR 820.5021 CFR 211.22(d)

Full citation text and observation details available on the Dashboard.

Other documents for NATCO Pharma Limited
  • 483 - 2025-06-19June 19, 2025
  • 483 - 2023-10-18October 18, 2023
  • 483 - 2019-06-05June 5, 2019
  • 483 - 2017-01-24January 24, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore NATCO Pharma Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.